Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

We are advancing programs in women’s health, including  egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy in women with uterine fibroids or endometriosis.

Over time, we intend to expand our development pipeline to include potential treatments for women's health.

Data Provided by Refinitiv. Minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
November 16, 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
November 16, 2022
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
October 26, 2022
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
Events

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA